1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsModulation of Liver Metabolism/Inflammation at Different Disease Stages by Leveraging ADAR-based RNA Editing is sponsored by European Research Council (ERC). This ERC-funded project aims to modulate liver metabolism and inflammation at various disease stages using ADAR-based RNA editing techniques.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Synergy Grant from the European Research Council for an Application-Oriented Project in Medicine | Universitätsklinikum Tübingen Synergy Grant from the European Research Council for an Application-Oriented Project in Medicine Success with a Synergy Grant: The Tübingen researchers Thorsten Stafforst (left) and M3 Scientific Director Mathias Heikenwälder (right). Liver diseases are on the rise worldwide.
A research team led by Professor Thorsten Stafforst and Professor Mathias Heikenwälder from the Cluster of Excellence “Image-guided and Functionally Instructed Tumor Therapies” (iFIT) at the University of Tübingen, together with Professor Erez Levanon from Bar-Ilan University in Israel, aims to expand the currently insufficient therapeutic options in their new project “HepaModulatoR.
” Using RNA editing, a genetic engineering method, they intend to develop precise, safe, and personalized therapies against fatty liver disease, inflammation, and liver cancer. For this purpose, they have obtained a Synergy Grant from the European Research Council (ERC), which provides project funding of ten million euros over a period of six years.
With the Synergy Grants, the European Research Council funds collaborative projects which, due to their complexity, are conducted by several researchers and their groups in order to achieve breakthroughs that could not be reached in individual projects. Reversible alteration of genetic information The liver is considered the metabolic center of the body and possesses the ability to regenerate itself.
However, when it becomes unbalanced, the consequences are devastating: millions of people worldwide suffer from fatty liver, viral infections, or other chronic damage that can lead to liver cancer. Liver cancer is currently the fourth most frequent cause of cancer death—and the chances of recovery are still low.
In the HepaModulatoR project, the research team aims to tackle liver diseases at their molecular roots using the most modern RNA technologies. While so-called gene scissors permanently alter DNA, the stable carrier of genetic information, RNA editing uses a gentler approach. The genetic information in DNA is regularly transcribed into the intermediate molecule RNA within the cell, which then serves as a template for protein production.
The modification of RNA in corrective editing, however, remains temporary. “We want to help liver cells help themselves,” says Mathias Heikenwälder, Scientific Director at the M3 Research Center of the Medical Faculty of Tübingen and a recognized expert on liver inflammation. “If we can control disease processes early and precisely, we create completely new possibilities for the treatment of chronic liver diseases.
” Thorsten Stafforst from the Institute of Biochemistry at the University of Tübingen and founding member of the Tübingen Center for Gene and RNA Therapy, emphasizes: “Our vision is to develop RNA drugs that can flexibly adapt to different stages of disease. We combine molecular precision with clinical applicability—this is unique in Europe.
” The Tübingen researchers and Erez Levanon are working toward the common goal of developing new RNA medicines that reprogram liver cells in different stages of disease—from disturbed metabolism to tumor growth. Three approaches against liver diseases The research team is pursuing three main focuses. In the early phase, liver metabolism is to be stabilized so that fats and sugars do not accumulate in a harmful way.
In intermediate stages, the aim is to slow down chronic inflammation in order to protect liver tissue, and in late stages, when cancer develops, the immune system is to be activated to specifically destroy tumor cells. This combination of prevention, regulation, and immune activation could open up completely new therapeutic pathways—especially for patients for whom conventional treatments fail.
Cutting-edge research from Tübingen The iFIT Cluster of Excellence, to which both Tübingen researchers belong, is Germany’s only oncology-focused Cluster of Excellence devoted entirely to cancer research. This environment offers outstanding infrastructure and promotes close cooperation between different disciplines.
Heikenwälder’s laboratory contributes decades of experience with models of liver inflammation and cancer, while Stafforst’s team is regarded internationally as a pioneer in RNA editing. He has also founded the biotech start-up AIRNA, in which RNA editing methods are being translated into clinical application.
Together, Stafforst and Heikenwälder combine their expertise to precisely modulate liver metabolism and the immune system in different stages of disease. In the long term, the HepaModulatoR project aims, beyond its concrete research on liver diseases, to demonstrate that RNA-based medicine can serve as a tool for many diseases—safe, flexible, and tailored to the individual. “We are only at the beginning,” says Heikenwälder.
“But if we can understand how to correctly interpret and modify the language of cells at the RNA level, then this is nothing less than a paradigm shift in medicine.
” Based on a press release by the University Hospital Tübingen / JE, University Communications The project “Modulation of Liver Metabolism/Inflammation at Different Disease Stages by Leveraging ADAR-based RNA Editing” (HepaModulatoR) will be funded by a Synergy Grant of the European Research Council from 2026 to 2032 with approximately ten million euros.
According to the current listing, eligibility includes: Nonprofit research institutions in EU member states. Confirm the full requirements in the official notice before applying.
The current listing shows €9,969,748. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Modulation of Liver Metabolism/Inflammation at Different Disease Stages by Leveraging ADAR-based RNA Editing is funded by European Research Council (ERC). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Diabetes, Digestive, Kidney Extramural Research - Research Centers is sponsored by Department of Health And Human Services. To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. Specific programs areas of interest include the following: (a) For diabetes, endocrine, and metabolic diseases areas: Fundamental and clinical studies including the etiology, pathogenesis, prevention, diagnosis, treatment and cure of diabetes mellitus and its complications; Normal and abnormal function of the pituitary, thyroid, parathyroid, adrenal, and other hormone secreting glands; Hormonal regulation of bone, adipose tissue, and liver; on fundamental aspects of signal transduction, including the action of hormones, coregulators, and chromatin remodeling proteins; Hormone biosynthesis, secretion, metabolism, and binding; and on hormonal regulation of gene expression and the role(s) of selective receptor modulators as partial agonists or antagonists of hormone action; and Fundamental studies relevant to metabolic disorders including membrane structure, function, and transport phenomena and enzyme biosynthesis; and basic and clinical studies on the etiology, pathogenesis, prevention, and treatment of inherited metabolic disorders (such as cystic fibrosis). (b) For digestive disease and nutrition areas: Genetics and genomics of the GI tract and its diseases; Genetics and genomics of liver/pancreas and diseases; Genetics and genomics of nutrition; genetics and genomics of obesity; Bariatric surgery; Clinical nutrition research; Clinical obesity research; Complications of chronic liver disease; Fatty liver disease; Genetic liver disease; HIV and liver; Cell injury, repair, fibrosis and inflammation in the liver; Liver cancer; Liver transplantation; Pediatric liver disease; Viral hepatitis and infectious diseases; Gastrointestinal and nutrition effects of AIDS; Gastrointestinal mucosal and immunology; Gastrointestinal motility; Basic neurogastroenterology; Gastrointestinal development; Gastrointestinal epithelial biology; Gastrointestinal inflammation; Digestive diseases epidemiology and data systems; Nutritional epidemiology and data systems; Autoimmune liver disease; Bile, Bilirubin and cholestasis; Bioengineering and biotechnology related to digestive diseases, liver, nutrition and obesity; Cell and molecular biology of the liver; Developmental biology and regeneration; Drug-induced liver disease; Gallbladder disease and biliary diseases; Exocrine pancreas biology and diseases; Gastrointestinal neuroendocrinology; Gastrointestinal transport and absorption; Nutrient metabolism; Pediatric clinical obesity; Clinical trials in digestive diseases; Liver clinical trials; Obesity prevention and treatment; and Obesity and eating disorders. (c) For kidney, urologic and hematologic diseases areas: Studies of the development, physiology, and cell biology of the kidney; Pathophysiology of the kidney; Genetics of kidney disorders; Immune mechanisms of kidney disease; Kidney disease as a complication of diabetes; Effects of drugs, nephrotoxins and environmental toxins on the kidney; Mechanisms of kidney injury repair; Improved diagnosis, prevention and treatment of chronic kidney disease and end-stage renal disease; Improved approaches to maintenance dialysis therapies; Basic studies of lower urinary tract cell biology, development, physiology, and pathophysiology; Clinical studies of bladder dysfunction, incontinence, pyelonephritis, interstitial cystitis, benign prostatic hyperplasia, urolithiasis, and vesicoureteral reflux; Development of novel diagnostic tools and improved therapies, including tissue engineering strategies, for urologic disorders; Research on hematopoietic cell differentiation; metabolism of iron overload and deficiency; Structure, biosynthesis and genetic regulation of hemoglobin; as well as Research on the etiology, pathogenesis, and therapeutic modalities for the anemia of inflammation and chronic diseases. This listing is currently active. Program number: 93.KRC. Last updated on 2026-01-30.
Diabetes, Digestive, and Kidney Diseases Extramural Research is sponsored by Department of Health And Human Services. (1) To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. Specific programs areas of interest include the following: (a) For diabetes, endocrine, and metabolic diseases areas: Fundamental and clinical studies including the etiology, pathogenesis, prevention, diagnosis, treatment and cure of diabetes mellitus and its complications; Normal and abnormal function of the pituitary, thyroid, parathyroid, adrenal, and other hormone secreting glands; Hormonal regulation of bone, adipose tissue, and liver; on fundamental aspects of signal transduction, including the action of hormones, coregulators, and chromatin remodeling proteins; Hormone biosynthesis, secretion, metabolism, and binding; and on hormonal regulation of gene expression and the role(s) of selective receptor modulators as partial agonists or antagonists of hormone action; and Fundamental studies relevant to metabolic disorders including membrane structure, function, and transport phenomena and enzyme biosynthesis; and basic and clinical studies on the etiology, pathogenesis, prevention, and treatment of inherited metabolic disorders (such as cystic fibrosis). (b) For digestive disease and nutrition areas: Genetics and genomics of the GI tract and its diseases; Genetics and genomics of liver/pancreas and diseases; Genetics and genomics of nutrition; genetics and genomics of obesity; Bariatric surgery; Clinical nutrition research; Clinical obesity research; Complications of chronic liver disease; Fatty liver disease; Genetic liver disease; HIV and liver; Cell injury, repair, fibrosis and inflammation in the liver; Liver cancer; Liver transplantation; Pediatric liver disease; Viral hepatitis and infectious diseases; Gastrointestinal and nutrition effects of AIDS; Gastrointestinal mucosal and immunology; Gastrointestinal motility; Basic neurogastroenterology; Gastrointestinal development; Gastrointestinal epithelial biology; Gastrointestinal inflammation; Digestive diseases epidemiology and data systems; Nutritional epidemiology and data systems; Autoimmune liver disease; Bile, Bilirubin and cholestasis; Bioengineering and biotechnology related to digestive diseases, liver, nutrition and obesity; Cell and molecular biology of the liver; Developmental biology and regeneration; Drug-induced liver disease; Gallbladder disease and biliary diseases; Exocrine pancreas biology and diseases; Gastrointestinal neuroendocrinology; Gastrointestinal transport and absorption; Nutrient metabolism; Pediatric clinical obesity; Clinical trials in digestive diseases; Liver clinical trials; Obesity prevention and treatment; and Obesity and eating disorders. (c) For kidney, urologic and hematologic diseases areas: Studies of the development, physiology, and cell biology of the kidney; Pathophysiology of the kidney; Genetics of kidney disorders; Immune mechanisms of kidney disease; Kidney disease as a complication of diabetes; Effects of drugs, nephrotoxins and environmental toxins on the kidney; Mechanisms of kidney injury repair; Improved diagnosis, prevention and treatment of chronic kidney disease and end-stage renal disease; Improved approaches to maintenance dialysis therapies; Basic studies of lower urinary tract cell biology, development, physiology, and pathophysiology; Clinical studies of bladder dysfunction, incontinence, pyelonephritis, interstitial cystitis, benign prostatic hyperplasia, urolithiasis, and vesicoureteral reflux; Development of novel diagnostic tools and improved therapies, including tissue engineering strategies, for urologic disorders;Research on hematopoietic cell differentiation; metabolism of iron overload and deficiency; Structure, biosynthesis and genetic regulation of hemoglobin; as well as Research on the etiology, pathogenesis, and therapeutic modalities for the anemia of inflammation and chronic diseases. (2) To encourage basic and clinical research training and career development of scientists during the early stages of their careers. The Ruth L. Kirschstein National Research Service Award (NRSA) funds basic and clinical research training, support for career development, and the transition from postdoctoral biomedical research training to independent research related to diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. (3) To expand and improve the Small Business Innovation Research (SBIR) program. The SBIR Program aims to increase and facilitate private sector commercialization of innovations derived from Federal research and development; to enhance small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. (4) To utilize the Small Business Technology Transfer (STTR) program. The STTR Program intends to stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. This listing is currently active. Program number: 93.847. Last updated on 2026-01-28.
Diabetes, Digestive, Kidney Extramural Research - Research Projects is sponsored by Department of Health And Human Services. To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases. Specific programs areas of interest include the following: (a) For diabetes, endocrine, and metabolic diseases areas: Fundamental and clinical studies including the etiology, pathogenesis, prevention, diagnosis, treatment and cure of diabetes mellitus and its complications; Normal and abnormal function of the pituitary, thyroid, parathyroid, adrenal, and other hormone secreting glands; Hormonal regulation of bone, adipose tissue, and liver; on fundamental aspects of signal transduction, including the action of hormones, coregulators, and chromatin remodeling proteins; Hormone biosynthesis, secretion, metabolism, and binding; and on hormonal regulation of gene expression and the role(s) of selective receptor modulators as partial agonists or antagonists of hormone action; and Fundamental studies relevant to metabolic disorders including membrane structure, function, and transport phenomena and enzyme biosynthesis; and basic and clinical studies on the etiology, pathogenesis, prevention, and treatment of inherited metabolic disorders (such as cystic fibrosis). (b) For digestive disease and nutrition areas: Genetics and genomics of the GI tract and its diseases; Genetics and genomics of liver/pancreas and diseases; Genetics and genomics of nutrition; genetics and genomics of obesity; Bariatric surgery; Clinical nutrition research; Clinical obesity research; Complications of chronic liver disease; Fatty liver disease; Genetic liver disease; HIV and liver; Cell injury, repair, fibrosis and inflammation in the liver; Liver cancer; Liver transplantation; Pediatric liver disease; Viral hepatitis and infectious diseases; Gastrointestinal and nutrition effects of AIDS; Gastrointestinal mucosal and immunology; Gastrointestinal motility; Basic neurogastroenterology; Gastrointestinal development; Gastrointestinal epithelial biology; Gastrointestinal inflammation; Digestive diseases epidemiology and data systems; Nutritional epidemiology and data systems; Autoimmune liver disease; Bile, Bilirubin and cholestasis; Bioengineering and biotechnology related to digestive diseases, liver, nutrition and obesity; Cell and molecular biology of the liver; Developmental biology and regeneration; Drug-induced liver disease; Gallbladder disease and biliary diseases; Exocrine pancreas biology and diseases; Gastrointestinal neuroendocrinology; Gastrointestinal transport and absorption; Nutrient metabolism; Pediatric clinical obesity; Clinical trials in digestive diseases; Liver clinical trials; Obesity prevention and treatment; and Obesity and eating disorders. (c) For kidney, urologic and hematologic diseases areas: Studies of the development, physiology, and cell biology of the kidney; Pathophysiology of the kidney; Genetics of kidney disorders; Immune mechanisms of kidney disease; Kidney disease as a complication of diabetes; Effects of drugs, nephrotoxins and environmental toxins on the kidney; Mechanisms of kidney injury repair; Improved diagnosis, prevention and treatment of chronic kidney disease and end-stage renal disease; Improved approaches to maintenance dialysis therapies; Basic studies of lower urinary tract cell biology, development, physiology, and pathophysiology; Clinical studies of bladder dysfunction, incontinence, pyelonephritis, interstitial cystitis, benign prostatic hyperplasia, urolithiasis, and vesicoureteral reflux; Development of novel diagnostic tools and improved therapies, including tissue engineering strategies, for urologic disorders; Research on hematopoietic cell differentiation; metabolism of iron overload and deficiency; Structure, biosynthesis and genetic regulation of hemoglobin; as well as Research on the etiology, pathogenesis, and therapeutic modalities for the anemia of inflammation and chronic diseases. This listing is currently active. Program number: 93.KRP. Last updated on 2026-01-30.